Evaluate Vantage Homepage
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.